RORA-Tscm CAR-T
Multiple Myeloma
Pre-clinicalActive
Key Facts
About RORABio
RORABio is a private, preclinical biotech spin-out from Case Western Reserve and Emory University, founded in 2021 (operating under a name established in 2004). The company's core asset is the RORA-Tscm platform, a proprietary manufacturing process for a stem-like T-cell population associated with improved clinical outcomes. RORABio is pursuing two primary applications: a bispecific CAR-T for multiple myeloma and a CCR5-edited T-cell therapy for HIV immune reconstitution, with the latter supported by a Gates Foundation grant to Emory. The company is led by a team with deep experience in cell therapy and oncology.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |